CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC
- Status
- UNKNOWN
- Phase
- N/A
Clinical Trials Related to HER2-positive Breast Cancer
Related studies linked through entity extraction aliases.
Safety of GQ1001 in Adult Patients With HER2-Positive Advanced Solid Tumors
- Status
- RECRUITING
- Phase
- PHASE1
MARGetuximab Or Trastuzumab (MARGOT)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
DS-8201a for trEatment of aBc, BRain Mets, And Her2[+] Disease
- Status
- COMPLETED
- Phase
- PHASE2
Feasibility of Chemotherapy De-escalation in Early-Stage HER2 Positive Breast Cancer
- Status
- WITHDRAWN
- Phase
- PHASE2
An Expanded Access Study to Provide at Home Subcutaneous Administration of Pertuzumab and Trastuzumab Fixed-Dose Combination (PH FDC SC) for Patients With HER2-Positive Breast Cancer During the COVID-19 Pandemic
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer
- Status
- RECRUITING
- Phase
- PHASE1
Anti-HER2 Therapy + Fulvestrant/Capecitabine in Women With HR+, HER2+, Non-visceral Metastases Stage IV Breast Cancer
- Status
- NOT_YET_RECRUITING
- Phase
- PHASE3
Monitoring HER2+ Breast Cancer Neoadjuvant Treatment With Advanced PET/MRI
- Status
- RECRUITING
- Phase
- PHASE1
A Study to Measure the Expression of the HER2-HER3 Dimer in Tumour and Blood (Exosomes) Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies
- Status
- UNKNOWN
- Phase
- N/A
Markers to Evaluate the Efficacy of PH-based Regimen as a Neoadjuvant Therapy for Operable HER2 Positive Breast Cancer
- Status
- RECRUITING
- Phase
- NA
A First-in-human Study Using BDC-1001 as a Single Agent and in Combination With Nivolumab in Advanced HER2-Expressing Solid Tumors
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Genetic Characteristics of HER2 Positive Breast Cancer With Neoadjuvant TCHP Chemotherapy
- Status
- UNKNOWN
- Phase
- N/A
Monitoring Early Response to Targeted Therapy in Stage IV HER2+ Breast Cancer Patients With Advanced PET/MR Imaging
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
TAEK-VAC-HerBy Vaccine for Brachyury and HER2 Expressing Cancer
- Status
- COMPLETED
- Phase
- PHASE1
A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER+/HER2+ Breast Cancer.
- Status
- UNKNOWN
- Phase
- PHASE2
Avoiding Sentinel Lymph Node Biopsy in Breast Cancer Patients After Neoadjuvant Chemotherapy
- Status
- NOT_YET_RECRUITING
- Phase
- NA
Treatment Protocol of Tucatinib With Capecitabine and Trastuzumab in Patients With Unresectable Previously Treated HER2+ Breast Cancer
- Status
- APPROVED_FOR_MARKETING
- Phase
- N/A
Clinical Study of Recombinant Anti-HER2 Humanized Monoclonal Antibody for Injection
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 Alone
- Status
- UNKNOWN
- Phase
- PHASE2